Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.
The web-based survey is conducted in EU countries where Mayzent (siponimod) is available on the market and reimbursed for at least 6 months, to capture the knowledge and understanding of specific Mayzent safety measures by HCPs and patients/caregivers with access to Mayzent (siponimod).
Physicians will be considered eligible for the survey if they meet the following screening criteria:
Care for relapsing MS (RMS) patients
Personally prescribed disease modifying therapies to MS patients, and;
Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.
Nurses will be considered eligible for the survey if they:
Provide supportive care for RMS patients
Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.
Patient inclusion criteria include:
- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement
Novartis Investigative Site